BIO
Price
$386.13Alerts
Change
-$0.35 (-0.09%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
10.2B
98 days until earnings call
Intraday BUY SELL Signals
BRKRP
Price
$455.88Alerts
Change
+$1.71 (+0.38%)
Updated
Nov 11 closing price
Capitalization
N/A
Intraday BUY SELL Signals
Interact to see
Advertisement

BIO vs BRKRP

BIO vs BRKRP Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BIO vs. BRKRP commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIO is a StrongBuy and BRKRP is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BIO with price predictions
Nov 11, 2026

BIO in upward trend: 10-day moving average crossed above 50-day moving average on November 04, 2026

The 10-day moving average for BIO crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on BIO as a result. In 69 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.

The Moving Average Convergence Divergence (MACD) for BIO just turned positive on October 23, 2026. Looking at past instances where BIO's MACD turned positive, the stock continued to rise in 36 of 50 cases over the following month. The odds of a continued upward trend are 72%.

BIO moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

BIO broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 15 (best 1 - 100 worst), indicating outstanding price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.422) is normal, around the industry mean (4.142). P/E Ratio (46.363) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for BRKRP with price predictions
Nov 11, 2026

BRKRP in upward trend: price rose above 50-day moving average on November 06, 2026

BRKRP moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 8 of 8 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 11 of 13 cases where BRKRP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on BRKRP as a result. In 13 of 18 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 72%.

The Moving Average Convergence Divergence (MACD) for BRKRP just turned positive on November 04, 2026. Looking at past instances where BRKRP's MACD turned positive, the stock continued to rise in 8 of 12 cases over the following month. The odds of a continued upward trend are 67%.

The 10-day moving average for BRKRP crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

Following a +13.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where BRKRP advanced for three days, in 46 of 56 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BRKRP declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

BRKRP broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (4.142). P/E Ratio (0.000) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.035) settles around the average of (0.011) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (40.124).

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. BRKRP’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BRKRP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BIO: Fundamental Ratings
BIO
OUTLOOK RATING
1..100
30
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
87
PRICE GROWTH RATING
1..100
15
P/E GROWTH RATING
1..100
2
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BIOBRKRP
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
72%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
66%
Bearish Trend 1 day ago
61%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
88%
Advances
ODDS (%)
Bullish Trend 3 days ago
65%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 1 day ago
69%
Bearish Trend 10 days ago
69%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
77%
Aroon
ODDS (%)
Bearish Trend 1 day ago
68%
N/A
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (BIO: $386.00 vs. BRKRP: $455.88)
Brand notoriety: BIO and BRKRP are both not notable
Both companies represent the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: BIO: 81% vs. BRKRP: 2%
Market capitalization -- BIO: $10.2B vs. BRKRP: $0
BIO [@Medical/Nursing Services] is valued at $10.2B. BRKRP’s [@Medical/Nursing Services] market capitalization is $0. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $837 to $190.22B. The average market capitalization across the [@Medical/Nursing Services] industry is $6.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIO’s FA Score shows that 2 FA rating(s) are green while BRKRP’s FA Score has 1 green FA rating(s).

  • BIO’s FA Score: 2 green, 3 red.
  • BRKRP’s FA Score: 1 green, 4 red.
According to our system of comparison, both BIO and BRKRP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIO’s TA Score shows that 5 TA indicator(s) are bullish while BRKRP’s TA Score has 6 bullish TA indicator(s).

  • BIO’s TA Score: 5 bullish, 4 bearish.
  • BRKRP’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, BRKRP is a better buy in the short-term than BIO.

Price Growth

BIO (@Medical/Nursing Services) experienced а +1.58% price change this week, while BRKRP (@Medical/Nursing Services) price change was -1.90% for the same time period.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.76%. For the same industry, the average monthly price growth was -4.63%, and the average quarterly price growth was -1.72%.

Reported Earning Dates

BIO is expected to report earnings on Feb 18, 2027.

Industries' Descriptions

@Medical/Nursing Services (-2.76% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

BIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, BIO has been closely correlated with A. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if BIO jumps, then A could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BIO
1D Price
Change %
BIO100%
-0.12%
A - BIO
68%
Closely correlated
-0.52%
RVTY - BIO
67%
Closely correlated
-0.53%
DHR - BIO
66%
Loosely correlated
-0.34%
MTD - BIO
64%
Loosely correlated
-0.14%
TMO - BIO
63%
Loosely correlated
-0.07%
More

BRKRP and

Correlation & Price change

A.I.dvisor indicates that over the last year, BRKRP has been loosely correlated with BRKR. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BRKRP jumps, then BRKR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BRKRP
1D Price
Change %
BRKRP100%
+0.38%
BRKR - BRKRP
55%
Loosely correlated
+0.27%
BIO - BRKRP
41%
Loosely correlated
-0.12%
PACB - BRKRP
33%
Poorly correlated
-6.70%
VMD - BRKRP
31%
Poorly correlated
+1.67%
CNMD - BRKRP
30%
Poorly correlated
-0.86%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VNOM41.130.94
+2.34%
Viper Energy
CNTB0.690.01
+0.98%
Connect Biopharma Holdings Limited
AVIR4.220.02
+0.48%
Atea Pharmaceuticals
TCBK51.92-0.42
-0.80%
TriCo Bancshares
FTAIM26.50-0.35
-1.30%
FTAI Aviation Ltd